SRR5088871
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- WNT_BETA_CATENIN_SIGNALING+0.200
- APICAL_SURFACE+0.100
- COAGULATION+0.100
- ESTROGEN_RESPONSE_LATE+0.100
- MYOGENESIS+0.100
- NOTCH_SIGNALING+0.100
- APICAL_JUNCTION+0.000
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- MTORC1_SIGNALING-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- ANDROGEN_RESPONSE-0.400
- COMPLEMENT-0.400
- INFLAMMATORY_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 718c4754-af81-496f-878d-83222a2581b8 | — | — | 0.919 |
| 2 | SRR5088900 | — | — | 0.880 |
| 3 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.876 |
| 4 | ERR4976607 | — | B | 0.873 |
| 5 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.873 |
| 6 | s0102877 | — | — | 0.869 |
| 7 | SRR650204 | — | — | 0.869 |
| 8 | SRR12202483 | — | — | 0.866 |
| 9 | SRR1335254 | GTEX | — | 0.866 |
| 10 | ea635e80-1225-4f52-a6cf-8f4c20201240 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |